-
Electronic (PDF)
-
Site License
-
Enterprisewide
Leukemia - A Therapeutic & Competitive Insight
Bioseeker, October 2006, Pages: 127
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry.
This has now clearly changed with the launch of Novartis’ Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.
Research and analysis highlights
In the report "Leukemia - A Therapeutic & Competitive Insight" The author does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide a insight and framework to understand the complex field of leukemia therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. The author presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.
Scope of this report
Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current and future treatment strategies
Anticancer pipeline of most companies in the field
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in leukemia R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities associated with leukemia therapy
- More than 130 high quality references
Some of the drugs included in this analysis
AG-858, Alemtuzumab, AP23573, Atra, Avastin, BAY 43-9006, CEP-701, Ceplene, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, Imatinib, OSI-461, PKC412, PTK787, Rituximab, SU5416, Troxacitabine, Valspodar, VELCADE, Xcytrin and Zarnestra
1 Executive Summary
2 Cancer Highlights
3 Methodology
4 Table of Contents
4.1 List of Boxes
4.2 List of Table
5 Introduction
5.1 Disease Definitions
5.1.1 The Lymphoid Malignancies
5.1.2 The Myeloid Malignancies
5.2 Etiology & Pathophysiology
5.2.1 The Lymphoid Malignancies
5.2.2 The Myeloid Malignancies
5.3 Epidemiology
5.4 Prognosis
5.4.1 The Lymphoid Malignancies
5.4.2 The Myeloid Malignancies
6 Current Treatment Strategies
6.1 The Lymphoid Malignancies
6.2 The Myeloid Malignancies
7 Progress in Current Treatment Strategies
7.1 The Lymphoid Malignancies
7.2 The Myeloid Malignancies
8 Key Therapeutic Strategies for Future Therapies
8.1 Therapeutic type, Targets & Mechanisms
9 Competitive Landscape in Drug Development: The Late Stage Pipeline
9.1 The Lymphoid Malignancies
9.2 The Myeloid Malignancies
10 Current Drug Development: The Early Stage Pipeline
10.1 The Myeloid Malignancies
10.2 The Lymphoid Malignancies
11 Disclaimer
11.1 Liability
11.2 Completeness
12 Appendix: Drugs Approved for the Treatment of Leukemia: A Historical Perspective
13 Drug Index
14 Company Index
4.1 List of Boxes
40HBox 1: Major treatment regimes
41HBox 2: CLL staging system
42HBox 3: Updated REAL/WHO Classification for B-Cell Neoplasms
43HBox 4: Quick Facts - Clofarabine
4HBox 5: Quick Facts - Alemtuzumab
45HBox 6: Quick Facts - Gemtuzumab
46HBox 7: Quick Facts - Imatinib
47HBox 8: Quick Facts - Rituximab
48HBox 9: Quick Facts - Genasense
49HBox 10: Quick Facts - Flavopiridol
50HBox 11: Quick Facts - Atra
51HBox 12: Quick Facts - Gvax
52HBox 13: Quick Facts - Zarnestra
53HBox 14: Quick Facts – BAY 43-9006
54HBox 15: Quick Facts - Ceplene
5HBox 16: Quick Facts - Valspodar
56HBox 17: Quick Facts - CEP-701
57HBox 18: Quick Facts - PKC412
58HBox 19: Quick Facts - SU5416
59HBox 20: Quick Facts - PTK787
60HBox 21: Quick Facts - Cloretazine
61HBox 22: Company statement on progress
62HBox 23: Quick Facts - Troxacitabine
63HBox 24: Quick Facts - FK228
64HBox 25: Quick Facts - Decitabine
65HBox 26: Quick Facts - VELCADE
6HBox 27: Velcade sales 2005
67HBox 28: Quick Facts - AG-858
68HBox 29: Quick Facts - Avastin
Box 30: Quick Facts - OSI-461
70HBox 31: Quick Facts - Xcytrin
71HBox 32: Quick Facts - AP23573
4.2 List of Tables
72HTable 1: ALL Classification
73HTable 2: Latest Approved Drugs for the Treatment of Leukemia
74HTable 3: Kinase Inhibitors in Development for the Treatment of Leukemia
75HTable 4: Near Term Progress Rituximab
76HTable 5: Near Term Progress Oblimersen
7HTable 6: Near Term Progress Alvocidib
78HTable 7: Near Term Progress ATRA
79HTable 8: Near Term Progress GVAX
Table 9: Near Tearm Progress HuM195
Table 10: Near Term Progress Zarnestra
Table 11: Near Term Progress Sorafenib
Table 12: Near Term Progress Valspodar
Table 13: Summary of Current Late Stage Pipeline
Table 14: Near Term Progress CEP-701
Table 15: Near Term Progress PKC412
Table 16: Near Term Progress SU5416
Table 17: Near Term Progress PTK787
Table 18: Near Term Progress VNP40101M
Table 19: Near Term Progress Troxacitabine
Table 20: Near Term Progress Decitabine
Table 21 Near Term Progress Bortezomib
Table 22 Near Term Progress AG-858
Table 23: Near Term Progress bevacizumab
Table 24: Near Term Progress OSI-461
Table 25: Near Term Progress Xcytrin
Table 26: Near Term Progress AP23573
Table 27: Summary of Current Early Stage Pipeline
Some of the companies included in this analysis:
Amgen, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cephalon, Cyclacel Group (Cyclacel), Exelixis, Genta, GlaxoSmithKline, Johnson & Johnson, Millennium, Novartis, Pharmacyclics, PDL BioPharma, Schering-Plough, SuperGen, Vion Pharmaceuticals and Wyeth
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
